Table 1 Clinicopathological characteristics of the patients according to the level of inflammatory indices
Low NLR | High NLR | Low PLR | High PLR | Low CAR | High CAR | GPS: 0 | GPS: 1/2 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
N=58 (%) | N=59 (%) | P-value | N=58 (%) | N=59 (%) | P-value | N=58 (%) | N=59 (%) | P-value | N=104 (%) | N=13 (%) | P-value | |
Sex | 0.017* | 0.401 | 0.220 | 0.292 | ||||||||
Male | 31 (53.4%) | 44 (74.6%) | 35 (60.3%) | 40 (67.8%) | 34 (58.6%) | 41 (69.5%) | 65 (62.5%) | 10 (76.9%) | ||||
Female | 27 (46.6%) | 15 (25.4%) | 23 (39.7%) | 19 (32.2%) | 24 (41.4%) | 18 (30.5%) | 39 (37.5%) | 3 (23.1%) | ||||
Age (median, range), years | 66 (38-81) | 66 (33-83) | 0.595 | 65.5 (33-81) | 67 (41-83) | 0.754 | 68 (33-83) | 64 (38-83) | 0.196 | 65.5 (33-83) | 70 (45-83) | 0.146 |
BMI (median, IQR) | 21.9 (20.1-23.5) | 22.1 (20.3-25.6) | 0.460 | 23.2 (20.5-24.8) | 21.2 (19.6-24.2) | 0.096 | 22.5 (20-23.9) | 21.8 (20.4-25.5) | 0.639 | 21.8 (20.1-24) | 23.6 (21-25.8) | 0.204 |
Primary tumor location | 0.955 | 0.439 | 0.720 | 0.355 | ||||||||
Right sided | 16 (27.6%) | 16 (27.1%) | 14 (24.1%) | 18 (30.5%) | 15 (25.9%) | 17 (28.8%) | 27 (26%) | 5 (38.5%) | ||||
Left sided | 42 (72.4%) | 43 (72.9%) | 44 (75.9%) | 41 (69.5%) | 43 (74.1%) | 42 (71.2%) | 77 (74%) | 8 (61.5%) | ||||
NAC | 0.521 | 0.162 | 0.045* | 0.457 | ||||||||
No | 33 (56.9%) | 37 (62.7%) | 31 (53.4%) | 39 (66.1%) | 40 (69%) | 30 (50.8%) | 61 (58.7%) | 9 (69.2%) | ||||
Yes | 25 (43.1%) | 22 (37.3%) | 27 (46.6%) | 20 (33.9%) | 18 (31%) | 29 (49.2%) | 43 (41.3%) | 4 (30.8%) | ||||
Preoperative CEA (median, IQR) | 8.8 (3.7-19.7) | 12.5 (3.9-45.2) | 0.089 | 8.8 (3.7-19.8) | 12.3 (5.1-47.9) | 0.055 | 8.8 (.6-28.3) | 12.2 (4.5-34) | 0.263 | 9.4 (3.9-26.4) | 1.3 (3.7-174.9) | 0.192 |
Onset | 0.778 | 0.646 | 0.646 | 0.896 | ||||||||
Metachronous | 27 (46.6%) | 29 (49.2%) | 29 (50%) | 27 (45.8%) | 29 (50%) | 27 (45.8%) | 50 (48.1%) | 6 (46.2%) | ||||
Synchronous | 31 (53.4%) | 30 (50.8%) | 29 (50%) | 32 (54.2%) | 29 (50%) | 32 (54.2%) | 54 (51.9%) | 7 (53.8%) | ||||
Metastatic tumor location | 0.074 | 0.306 | 0.619 | 1.000 | ||||||||
Bilobar | 27 (46.6%) | 18 (30.5%) | 25 (43.1%) | 20 (33.9%) | 21 (36.2%) | 24 (40.7%) | 40 (38.5%) | 5 (38.5%) | ||||
Hemilobar | 31 (53.4%) | 41 (69.5%) | 33 (56.9%) | 39 (66.1%) | 37 (63.8%) | 35 (59.3%)) | 64 (61.5%) | 8 (61.5%) | ||||
Liver tumor diameter (median, IQR) | 25 (17.8-39.3) | 25 (20-53) | 0.197 | 24 (15-34.3) | 33 (22-60) | 0.0011* | 23 (16.8-32.3) | 38 (22-61) | <.0001* | 25 (20-40) | 60 (21.5-87.5) | 0.011* |
Tumor number | 0.408 | 0.648 | 0.408 | 0.556 | ||||||||
Solitary | 29 (50%) | 25 (42.4%) | 28 (48.3%) | 26 (44.1%) | 29 (50%) | 25 (42.4%) | 47 (45.2%) | 7 (53.8%) | ||||
Multiple | 29 (50%) | 34 (57.6%) | 30 (51.7%) | 33 (55.9%) | 29 (50%) | 34 (57.6%) | 57 (54.8%) | 6 (46.2%) |